These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30782385)

  • 21. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW; Zachariae C; Simonsen AB
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract]   [Full Text] [Related]  

  • 22. Bullous pemphigoid induced by pembrolizumab in a patient with non-small-cell lung cancer who achieved durable complete response despite treatment cessation and long-term corticosteroid administration: A case report.
    Muto Y; Namikawa K; Fujiwara Y; Mori T; Nakano E; Takahashi A; Yamazaki N
    J Dermatol; 2020 Jan; 47(1):e9-e11. PubMed ID: 31674068
    [No Abstract]   [Full Text] [Related]  

  • 23. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab: a case report.
    Osman GA; Marra A; Iacono D; Giannelli V; Ricciardi S; Remotti D; Vecchione A; Ricci A; Palange P; Migliorino MR
    Anticancer Drugs; 2019 Aug; 30(7):e0764. PubMed ID: 30950836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyponatremia in a Patient With Cancer.
    Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
    Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
    [No Abstract]   [Full Text] [Related]  

  • 29. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
    Zhang D; Zhang Y; Huang Y; Kong L; Yu J
    Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    Boozalis E; Kwatra SG; Marrone KA
    JAMA Oncol; 2019 Feb; 5(2):261-262. PubMed ID: 30286225
    [No Abstract]   [Full Text] [Related]  

  • 31. Development of Thyroid Carcinoma During Treatment With Pembrolizumab in a Lung Cancer Patient.
    Gorospe L; García-Gómez-Muriel I; Pian-Arias HG; Gómez-Ramírez J; Rioja-Martín ME; Olmedo-García ME; Garrido-López P; Muñoz-Molina GM; Mezquita L
    Ann Thorac Surg; 2020 Jun; 109(6):e397-e399. PubMed ID: 31846639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
    Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
    Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esophagitis in Non-Small Cell Lung Carcinoma Treatment Caused by Pembrolizumab.
    Yoshida S; Miyamoto S; Naruse H; Ito J; Kinosita K; Kudo T; Hatanaka K; Yamamoto Y; Sakamoto N
    Am J Gastroenterol; 2020 Jan; 115(1):13. PubMed ID: 31356230
    [No Abstract]   [Full Text] [Related]  

  • 34. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab.
    Curioni-Fontecedro A; Ickenberg C; Franzen D; Rogler G; Burger IA; van den Broek M
    Ann Oncol; 2017 Aug; 28(8):2040-2041. PubMed ID: 28838208
    [No Abstract]   [Full Text] [Related]  

  • 38. Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
    Khalife N; Kordahi M; Felefly T; Saleh K
    Future Oncol; 2021 Jul; 17(20):2559-2562. PubMed ID: 34047193
    [No Abstract]   [Full Text] [Related]  

  • 39. Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
    Yaga M; Shiroyama T; Hirata H; Oya K; Takeda Y; Kumanogoh A
    Clin Lung Cancer; 2022 Mar; 23(2):e116-e117. PubMed ID: 34980563
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
    J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.